Lapatinib is a new biologic drug for the treatment of?advanced?breast cancer .
Its mechanism of action is based on inhibiting the action of the epidermal growth factor receptor protein (HER2), which is present in 25% of patients with breast cancer. The excess protein causes cells to overproduce and eventually spreads throughout the body.
Unlike?trastuzumab??, it is not about an antibody that binds to a specific antigen on the cell membrane, but about a small molecule that enters the cell membrane and acts on several receptors simultaneously with the aim of blocking the normal activity of the cell and preventing its proliferation.

Trade name	Company name
TYKERB 250MG FC TABLETS	GLAXO

EGFR inhibitors

...
HER2 inhibitors

...

Gen name	Trade name	Catagory name
lapatinib	Tykerb	EGFR inhibitors
lapatinib	Tykerb	HER2 inhibitors
Lapatinib	TYKERB 250MG FC TABLETS

Gen name	trade name	catogry
neratinib	Nerlynx	HER2 inhibitors
trastuzumab	Herceptin	HER2 inhibitors
hyaluronidase / trastuzumab	Herceptin Hylecta	HER2 inhibitors
dacomitinib	Vizimpro	HER2 inhibitors
trastuzumab	Trazimera	HER2 inhibitors
pertuzumab	Perjeta	HER2 inhibitors
trastuzumab	Ogivri	HER2 inhibitors
ado-trastuzumab emtansine	Kadcyla	HER2 inhibitors
fam-trastuzumab deruxtecan	Enhertu	HER2 inhibitors
lapatinib	Tykerb	HER2 inhibitors
tucatinib	Tukysa	HER2 inhibitors
hyaluronidase / pertuzumab / trastuzumab	Phesgo	HER2 inhibitors
trastuzumab	Ontruzant	HER2 inhibitors
margetuximab	Margenza	HER2 inhibitors
trastuzumab	Herzuma	HER2 inhibitors
erlotinib	Tarceva	EGFR inhibitors
osimertinib	Tagrisso	EGFR inhibitors
neratinib	Nerlynx	EGFR inhibitors
gefitinib	Iressa	EGFR inhibitors
cetuximab	Erbitux	EGFR inhibitors
panitumumab	Vectibix	EGFR inhibitors
dacomitinib	Vizimpro	EGFR inhibitors
mobocertinib	Exkivity	EGFR inhibitors
lapatinib	Tykerb	EGFR inhibitors
necitumumab	Portrazza	EGFR inhibitors
vandetanib	Caprelsa	EGFR inhibitors